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Received June 16, 2011; accepted May 24, 2012AbstractBackground: The proper use of statins and aspirin decrease the risk of coronary heart disease (CHD) among patients with diabetes (DM) and
hyperlipidemia. The purpose of this study was to analyze the time trends and determinants of prescribing statins and aspirin among patients with
DM and hyperlipidemia in medical practice in Taiwan.
Methods: A cohort of 21,667 patients with DM and hyperlipidemia during the period from 1998 to 2006 was identified by using data of
ambulatory care claims from Taiwan’s National Health Insurance Database. The dataset was categorized into two equal calendar periods: Period
1 (September 1998eJune 2002) and Period 2 (July 2002eApril 2006). Multivariate logistic regression analyses were used to determine the
independent determinants associated with receipt of lipid-lowering agents and aspirin among these patients.
Results: There were significant increases in the prescribing of statins (OR 1.78; 95% CI 1.661.91) and aspirin (OR 1.47, 95% CI 1.501.59) in
Period 2 as compared with Period 1. Nevertheless, 30% of patients with coexisting CHD neither received statins nor aspirin. Only 15% to 25% of
DM patients with hyperlipidemia and CHD received the combined treatment with aspirin and statin. In multivariate logistic regression, we found
that women received aspirin less frequently than men. Old patients (>45 years) with concomitant CHD were more likely to receive statins and
aspirin.
Conclusion: Despite the increasing trend in the use of statins and aspirin in DM patients with hyperlipidemia in Taiwan, the improvements were
at best modest, particularly for secondary prevention. Our data indicate the need for continued efforts to improve the utilization of these drugs in
daily practice.
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The burden of coronary heart disease (CHD) in patients
with diabetes (DM) is substantial. Patients with DM are
associated with a 2- to 4-fold increase in the incidence of CHD
and have an elevated risk of premature death compared with
people without DM.1e3 Existing evidence convincingly
indicates that DM patients can benefit from treatments ofhinese Medical Association. All rights reserved.
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(statins) in both primary and secondary prevention of CHD.4
The role of aspirin therapy in the secondary prevention of
cardiovascular events in DM patients is also well established.5
Furthermore, Hennekens et al.6 found that there were additive
benefits from the combined use of aspirin and a statin in the
secondary prevention of CHD, which were not present if either
agent were administered alone. Based on this compelling
evidence, the Adult Treatment Panel III (ATP III) of the
National Cholesterol Education Program (NCEP) has strongly
recommend the use of statins and aspirin in patients with
diabetic dyslipidemia who already have concomitant CHD.7
Despite the widespread dissemination of the NCEP ATP III
guidelines, it has been suggested that aspirin and statins were
underutilized in patients with DM in practice.8e11 The reasons
for statins and aspirin being underutilized in the medical
community are unclear. Understanding the time trends and
factors associated with the prescription of statins and aspirin
among DM patients with hyperlipidemia may help to identify
subgroups worth targeting, such that more patients will
undergo drug therapies. The objectives of this study were to
evaluate the trends and the determinants of prescribing statins
and aspirin in patients with DM and hyperlipidemia over a 9-
year period from 1998 to 2006 in Taiwan, by using data of
ambulatory care claims from Taiwan’s National Health
Insurance (NHI) program.
2. Methods2.1. Study design and data sourceData were obtained from Taiwan’s NHI database, which
was maintained by the National Health Research Institutes
(NHRI) and overseen by the state-run Bureau of NHI for
research purposes.12 The NHI program in Taiwan was started
in 1995 and covered 23 million beneficiaries (almost 99.5% of
the population) by the end of 2009.13 The NHI claim datasets
provide Taiwan-based information on diseases and prescrip-
tion details to researchers. With ethical approval from the
NHRI, we used data from ambulatory care claims
(1998e2006) for the current study. The dataset was a repre-
sentative sample of the national outpatient insurance claims.
The NHRI employed a systemic random sampling method
retrieving 1 in 500 records of outpatient visits in the NHI
program, together with the related details of medical orders for
those patients. The Bureau performed periodic reviews on
a random sample of every 50e100 claims in each contracted
hospital and clinic for quality assurance, and false diagnostic
reports triggered a considerable penalty. The dataset we used
in this study included information on patients’ age, gender,
diagnostic codes, and prescription details over a period of 92
months (September 1998 to April 2006). The dataset was
categorized into two equal calendar periods (each spanned 46
months): Period 1 (September 1998eJune 2002) and Period 2
(July 2002eApril 2006), comparing the trends in drug
prescriptions. Each patient’s personal identification number
was replaced by a dummy number, and the same patient keptthe same dummy number in the dataset. All patients had to be
older than 20 years to be included in the study. To avoid
duplicated information, the data from the same patient were
only allowed to be sampled once in the dataset. If a patient
was sampled more than one time during the 92-month period,
only the outpatient data of the earliest date was counted, and
the repeated sample data (about 0.5% of the total information
volume) were excluded from the analyses.
The clinical diagnoses of the patients were coded by using
the International Classification of Disease, ninth revision
(ICD-9-CM) post-1995, and the A code (abridged code) prior
to 2000. Patients with concurrent diagnoses of diabetes (ICD-
9-CM 250.00e250.99 and A181) and hyperlipidemia (ICD-9-
CM 272.0e272.4 and A182 and A189) were included in the
analyses. The patients were further subdivided into those with
or without CHD (ICD-9-CM 410.0e414.95 and A 270 and
A279) in the analyses. Drug prescriptions were coded by using
the National Drug Codes in the NHI program.13 The lipid-
lowering drugs included in the study were categorized into
statins (including atorvastatin, fluvastain, lovastatin, pravas-
tatin, rosuvastatin, and simvastatin) and fibrates (bezafibrate,
clofibrate, etofibrate, fenofibrate, and gemfibrozil). Among the
statins, only rosuvastatin has been reimbursed since 2005, the
others were all reimbursed before 1998. All fibrates listed in
the study were available in Taiwan before 1998. Those patients
who had received any dose of aspirin (taken orally) were
considered aspirin users in the study.2.2. Statistical analysisData are expressed as mean (SD) or n (%). Categorical
variables were compared by c2 test and continuous variables
were compared by one-way analysis of variance or Student t
test. Univariate analyses were performed to choose potential
markers of medication prescriptions (data not shown). Vari-
ables with p< 0.05 on univariate analysis, including age (65
years, 45e64 years vs. <45 years), gender (men vs. women),
periods (Period 2 vs. Period 1), CHD (yes vs. no), and total
medication costs per visit (US$ 4 vs. >US$ 4; US$ 4 being
the median value), were entered into multivariate logistic
regression models to identify the independent determinants
associated with the prescribing of lipid-lowering agents and
aspirin among patients with DM and hyperlipidemia. For all
regression analyses, adjusted odds ratios and 95% confidence
intervals were reported. All analyses were performed using
SAS version 9.2 (SAS Institute, Cary, NC, USA). A p value of
< 0.05 was considered statistically significant.
3. Results
A study cohort of 21,667 patients with concomitant DM
and hyperlipidemia during 1998 to 2006 was identified, and
the process of patient selection for analysis was displayed in
Fig. 1. The characteristics of these patients are summarized in
Table 1. Among study participants, 5.5% of patients in Period
1 and 5.2% in Period 2 had CHD, with men exceeding women
in acquiring the disease ( p< 0.01). The time trends and
Fig. 1. Study flow diagram of patient selection for the analysis. NHI¼Na-
tional Health Insurance program. *If a patient was sampled more than once
during the 92-month study period, only the outpatient data of the earliest date
were included, and the repeated sampled data were excluded from the
analyses.
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the study patients with or without CHD between the two
periods are shown in Fig. 2. There were significant increases in
prescribed statins and aspirin in Period 2 as compared with
that in Period 1 ( p< 0.01 for all comparisons). Nevertheless,
it is noteworthy that 30% of all patients with CHD did not
receive a statin or aspirin. The prescribing of fibrates
decreased significantly from Period 1 to Period 2, among
patients both with and without CHD. The proportions of
patients who received both aspirin and a statin during the two
study periods are shown in Fig. 3. Only 15% to 25% of DM
patients with hyperlipidemia and CHD received combined
treatment with aspirin and statin. Moreover, the combined useTable 1
Characteristics of 21,667 patients with diabetes and hyperlipidemia in Taiwan,
1998e2006.
Periods Period 1 (n¼ 6202)
(September 1, 1998eJune
30, 2002)
Period 2 (n¼ 15,465)
(July 1, 2002eApril 30,
2006)
CHD CHD CHD CHD
() (þ) () (þ)
Number of patients 5862 340 14,659 806
Women (%) 3178 (54%) 157 (46%) 7792 (53%) 358 (44%)
Age (y) 59.2 (11.9) 62.5 (11.0) 60.0 (11.8) 64.0 (10.7)
Age groups
20e44 y 689 (12%) 21 (6%) 1397 (9%) 30 (4%)
45e64 y 3086 (53%) 167 (49%) 7882 (54%) 381 (47%)
65 y 2087 (35%) 152 (45%) 5380 (37%) 395 (49%)
Total numbers of
prescriptions
35,738 2,356 93,099 5,877
Data are expressed as mean (SD) or n (%).
CHD¼ coronary heart disease.of statin and aspirin for primary prevention was uncommon in
the study cohort, where <10% of patients with DM and
hyperlipidemia received both agents.
In the multivariate logistic regression models (Table 2), the
percentage of patients with DM and hyperlipidemia who
received statins and aspirin increased significantly from Period
1 to Period 2 (all p< 0.0001), while the percentage of DM
patients who received fibrates decreased by 20% in the latter
period. Old patients (>45 years old) with coexisting CHD
were more likely to have statins and aspirin prescribed to
them. In addition, men had a higher probability of receiving
fibrates and aspirin compared to women. Of note, the
prescribing of lipid-lowering drugs (both statins and fibrates)
was significantly associated with more costly prescriptions.
However, the receipt of aspirin was highly associated with
lower-cost prescriptions (Table 2).
4. Discussion
We found that during the 9-year study period, the
prescribing of statins among ambulatory patients with DM and
CHD increased from 30% to 40%, and the use of aspirin
increased from 40% to 50% (Fig. 2). The magnitude of rise in
the use of aspirin and statins was modest, particularly for
secondary prevention. For context, however, it is important to
understand that underutilization of statins and aspirin in
patients with DM in Taiwan was not a country-specific
issue.9e11 For example, Bolka et al10 estimated the preva-
lence of regular aspirin use among adults with diagnosed DM
in the United States and found that aspirin was used by 37% of
those with DM and CHD and by 13% of those with one or
more CHD risk factors. Additionally, Berthold et al11 assessed
statin prescription in 51,640 patients with DM in a German
registry. They reported that <40% of patients with DM and
established atherosclerotic disease received statins for
secondary prevention, and only 18% of patients were put on
statins for primary prevention. The causes of undertreatment
with aspirin and statins among people with DM remain
unclear. Multiple reasons may account for the widespread
underutilization of these drugs. Exploring the factors associ-
ated with aspirin and statin use might help identify patients
who will be more or less inclined to receive the medications.
We identified that women with DM and hyperlipidemia
received aspirin less frequently than men (Table 2). The
decreased aspirin prescription in women could partially be
attributed to the gender difference in absolute numbers of
patients who needed aspirin for secondary prevention, since
men were associated with a higher prevalence of CHD
compared with women (Table 1). In addition, the role of
aspirin for primary prevention of CHD in women is contro-
versial.14 Levin suggested that it would appear reasonable to
avoid prescribing aspirin as a primary preventive measure for
CHD in women unless their global risk for the disease was
very high.15 Apparently, there are many practitioners who
subscribe to this recommendation.
On the other hand, we found a significantly lower rate of
statins prescribed for men than for women (Table 2). The
Fig. 2. The temporal changes in the prescribing of statins, fibrates, and aspirin among patients with or without coronary heart disease (CHD) in Taiwan between
1998 and 2006. Upper panel: trends in treatments over time by study years. Lower pannel: Trends in treatments over time by study periods. Period 1: September 1,
1998eJune 30, 2002; Period 2: July 1, 2002eApril 30, 2006.
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indicating that many of the women we examined were post-
menopausal. In the Framingham Offspring Study, Schaefer
et al.16 demonstrated that women over the age of 50 surpassed
men in terms of the percentage of low-density lipoprotein
(LDL) cholesterol  160 mg/dL. The decrease in plasma
estrogen after menopause may play a significant role in the
reduction of LDLs clearance and subsequent increase in LDL-
cholesterol.16 Kolovou et al17 examined lipid profiles in 1385
dyslipidemia patients who did not receive lipid-lowering
agents. Their investigation found that hypertriglyceridemia
was more prevalent in men than women. Therefore, when lipid
profile was checked, men were more likely to receive fibrates
and women were more likely to receive statins for their lipid
problems, as is seen in the present study.
An analysis made by Hennekens et al6 revealed that, as
compared to statin monotherapy, an add-on aspirin therapy
further reduced the relative risk of CHD by 24% for secondary
prevention, while statin therapy provided an additional 13%
risk reduction as compared to aspirin monotherapy. Thecombination of aspirin and statins appears to confer greater
clinical benefits than either agent alone in term of secondary
prevention of CHD. However, we noticed that only 25% of the
patients with DM and CHD received such a treatment (Fig. 3).
It seems that this practice is not common in actual clinical
settings in Taiwan. Chang et al18 observed that there was
a significant increase in the prevalence of DM in Taiwan over
the years, from 5.3% in 1993 to 1996 to 9.1% in 2005 to 2008.
Considering the escalating disease burden of DM, we support
calls for a wider and more expansive use of aspirin and statins
in patients with DM.19
Osterberg and Blaschke20 have described that the health
care system may create barriers to medication utilization by
limiting access to prohibitively expensive drugs. Chou et al21
reported that the favorable trends towards higher levels of drug
utilization for patients with DM in Taiwan have been slowed
after the implementation of the NHI’s Global Budget Program
in 2002. In that program, the NHI negotiated an individual
expenditure cap with hospitals to control the growth of health
spending. Initially, we hypothesized that the total expenditure
Fig. 3. The temporal changes in the concomitant prescribing of statins and
aspirin among patients with or without coronary heart disease (CHD) in
Taiwan between 1998 and 2006. Period 1: September 1, 1998eJune 30, 2002;
Period 2: July 1, 2002eApril 30, 2006.
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causing medication underuse. The prescribing physicians
conceivably would not prescribe expensive medications such
as statins to the patients already taking other high-cost medi-
cations. Our data show that the uses of statins and fibrates
were associated with high total costs of drugs. Conversely, the
prescriptions of aspirin were associated with low total costs of
drugs (Table 2). When these medications were prescribed, it
appeared that the total costs of medications were not a major
consideration to the prescribing physicians. Overall, the
significance of these findings remains uncertain.Table 2
Variables associated with the prescribing of statins, fibrates, and aspirin among pa
Statins
Period
Period 2 vs. Period 1 1.80 (1.68e1.93)***
Age
20e44 y Reference
45e64 y 1.25 (1.13e1.39)***
65 y 1.26 (1.31e1.41)***
Gender
Men vs. women 0.81 (0.77e0.86)***
CHD
CHD vs. Non-CHD 1.24 (1.12e1.38)***
Total medication costs per visit
US$ 4 vs. >US$ 4 30.31 (26.34e34.88)***
Data presented are adjusted odds ratios (95% confidence intervals), which were ad
CHD¼ coronary heart disease.The strengths of this study include the nationwide repre-
sentative sample, the large sample size, and the detailed
prescription data. Nevertheless, several factors would have
biased our results. First, our dataset did not allow us to follow
up the same patient, and the nature of the dataset might lead to
an overestimation of the use of statins and aspirin, particularly
among those “high-risk” patients. If a patient visited the NHI
clinics more frequently than others, the individual would have
an increased likelihood of being sampled in the study dataset.
To minimize this potential problem, we employed a per-
patient-per-visit strategy in data analysis. The cross-sectional
nature of the data could also result in an underestimate of
the frequency of concomitant treatment with aspirin and statin
because both drugs might not be prescribed during the same
outpatient visit for an individual patient. However, the rates of
aspirin use for primary prevention observed in the study were
similar to that in the US,9 and the rates of statin use were close
to those reported by other studies.10,11 It seemed to us that the
magnitude of the above-mentioned overestimation or under-
estimation might not be substantial. Second, the datasets we
used did not have the patient lipid profile data. We used “the
diagnosis of hyperlipidemia” as a proxy of “high serum levels
of lipids” in the study. We acknowledge that coding hyper-
lipidemia was not an indicator of prescribing lipid-lowering
agents in the NHI program. The prescription rates of statins
and fibrates might be underestimated accordingly. Nonethe-
less, the time trends and the prescribing patterns remained
valid in the study because the proxy was used consistently
throughout the study periods. The use of aspirin could also be
underestimated because aspirin can be obtained without
a prescription. However, aspirin prescriptions are eligible for
reimbursement in Taiwan, the probability of obtaining over-
the-counter aspirin was likely to be low in the study. Finally,
the diffusion patterns of new drugs on the health care market
will certainly exert effects on the uses of these drugs.22
However, the impact of drug diffusion on aspirin and statin
utilizations in DM are beyond the scope of our study. Anyway,
the drugs involved in our study, except rosuvastatin, were all
available in Taiwan before 1998. Additionally, we did not havetients with diabetes and hyperlipidemia in Taiwan, 1998e2006.
Fibrates Aspirin
0.78 (0.72e0.84)*** 1.47 (1.35e1.59)***
Reference Reference
0.69 (0.62e0.77)*** 2.00 (1.69e2.37)***
0.47 (0.42e0.54)*** 2.43 (2.05e2.88)***
1.25 (1.16e1.35)*** 1.19 (1.11e1.28)***
0.73 (0.61e0.86)** 3.60 (3.27e3.97)***
10.26 (9.10e11.58)*** 0.004 (0.003e0.007)***
justed for all other variables listed in Table 2. **p< 0.01; ***p< 0.0001.
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among different regions of the country. We did not have the
patient admissions records, although the diagnosis of CHD
might actually be more accurate using claims of hospitaliza-
tion. These are limitations of our study.
In conclusion, we found that more than 50% of patients
with DM and hyperlipidemia did not receive statin treatments
in the current study. Only 15% to 25% of the study patients
with concomitant CHD received the combined treatment of
aspirin and statin for secondary prevention. We found that
men, patients younger than 45, and those without CHD were
less likely to receive statin therapy, and women were less
likely to receive aspirin. Given the increasingly prevalence of
DM in Taiwan, high priority should be given to improving the
use of aspirin and statins among patients with DM, especially
among those with concomitant CHD.
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